Recruiting studies: Pmmr

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07448142 Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unr
Phase 1 · 1 location(s) · Aaron Wolfson · NCT05603910 SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Ca
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06864013 Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab a
Phase 2 · 1 location(s) · Dechang Diao · NCT07005570 The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-re
Phase 2 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06266832 SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06850103 GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06558773 XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05970302 Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
Phase 2 · 1 location(s) · Shanghai Pudong Hospital · NCT07106034 Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capec
Phase 2 · 2 location(s) · Affiliated Cancer Hospital of Shantou University Medical Col · NCT07104604 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malign
Phase 1/Phase 2 · 13 location(s) · GV20 Therapeutics · NCT05669430 Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Phase 3 · 12 location(s) · Sun Yat-sen University · NCT05768503 Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Phase 2 · 1 location(s) · Zhejiang University · NCT05731726 Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients
Phase 1 · 2 location(s) · West China Hospital · NCT07510308 Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Can
Phase 2 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT06830239 Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Phase 2 · 2 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07718490 Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With
Phase 3 · 242 location(s) · National Cancer Institute (NCI) · NCT07198074 A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigati
Phase 1/Phase 2 · 14 location(s) · BioNTech SE · NCT07079631 Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tip
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06522919 Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MO
Phase 2/Phase 3 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06958432 Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06949111 Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who
Phase N/A · 1 location(s) · West China Hospital · NCT07105631 Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)
Phase 2 · 1 location(s) · Shandong Cancer Hospital and Institute · NCT07026422 Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
EARLY_Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07128355 - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Misma
Phase 2 · 23 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06856837 Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorect
Phase 2/Phase 3 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT06958419 Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-
Phase 2 · 5 location(s) · Yu jiren · NCT05872685 European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Ly
Phase N/A · 1 location(s) · Dr. Paul Buderath · NCT04504006 FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorect
Phase 3 · 24 location(s) · Gruppo Oncologico del Nord-Ovest · NCT06733038 Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR)
Phase 1 · 1 location(s) · Henry Smith · NCT07687875

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.